Teachers Retirement System of The State of Kentucky Has $3.23 Million Holdings in Kenvue Inc. (NYSE:KVUE)

Teachers Retirement System of The State of Kentucky trimmed its stake in Kenvue Inc. (NYSE:KVUE) by 0.8% in the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 139,658 shares of the company’s stock after selling 1,129 shares during the period. Teachers Retirement System of The State of Kentucky’s holdings in Kenvue were worth $3,230,000 at the end of the most recent reporting period.

Several other large investors have also bought and sold shares of KVUE. Sunbelt Securities Inc. increased its position in Kenvue by 3.1% during the 3rd quarter. Sunbelt Securities Inc. now owns 29,671 shares of the company’s stock valued at $686,000 after purchasing an additional 905 shares during the period. Financial Avengers Inc. boosted its stake in shares of Kenvue by 15.6% in the 3rd quarter. Financial Avengers Inc. now owns 46,530 shares of the company’s stock valued at $1,076,000 after purchasing an additional 6,278 shares during the last quarter. Coldstream Capital Management Inc. increased its position in shares of Kenvue by 2.6% during the third quarter. Coldstream Capital Management Inc. now owns 26,017 shares of the company’s stock worth $602,000 after buying an additional 653 shares during the period. Geode Capital Management LLC raised its stake in Kenvue by 0.9% during the third quarter. Geode Capital Management LLC now owns 44,677,077 shares of the company’s stock worth $1,029,810,000 after buying an additional 399,846 shares during the last quarter. Finally, M&T Bank Corp raised its stake in Kenvue by 4.6% during the third quarter. M&T Bank Corp now owns 106,594 shares of the company’s stock worth $2,465,000 after buying an additional 4,654 shares during the last quarter. 97.64% of the stock is owned by institutional investors.

Kenvue Stock Down 0.5 %

Kenvue stock opened at $22.21 on Friday. The company has a current ratio of 1.00, a quick ratio of 0.69 and a debt-to-equity ratio of 0.66. The firm’s fifty day moving average price is $22.95 and its two-hundred day moving average price is $21.20. The firm has a market capitalization of $42.58 billion, a price-to-earnings ratio of 40.38, a price-to-earnings-growth ratio of 2.02 and a beta of 1.36. Kenvue Inc. has a 1-year low of $17.67 and a 1-year high of $24.46.

Kenvue (NYSE:KVUE) last released its quarterly earnings results on Thursday, November 7th. The company reported $0.28 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.27 by $0.01. The business had revenue of $3.90 billion during the quarter, compared to the consensus estimate of $3.92 billion. Kenvue had a return on equity of 21.43% and a net margin of 6.88%. The company’s quarterly revenue was down .4% on a year-over-year basis. During the same quarter in the previous year, the business earned $0.31 EPS. On average, equities research analysts predict that Kenvue Inc. will post 1.07 earnings per share for the current fiscal year.

Kenvue Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Wednesday, November 27th. Shareholders of record on Wednesday, November 13th were paid a dividend of $0.205 per share. This represents a $0.82 annualized dividend and a yield of 3.69%. The ex-dividend date was Wednesday, November 13th. Kenvue’s dividend payout ratio (DPR) is presently 149.09%.

Analyst Upgrades and Downgrades

A number of analysts have commented on the stock. Bank of America upped their price target on shares of Kenvue from $24.00 to $27.00 and gave the company a “buy” rating in a research report on Tuesday, October 22nd. Deutsche Bank Aktiengesellschaft cut Kenvue from a “buy” rating to a “hold” rating and decreased their target price for the stock from $25.00 to $24.00 in a research note on Thursday. Piper Sandler boosted their price target on Kenvue from $20.00 to $21.00 and gave the company a “neutral” rating in a research note on Monday, September 23rd. Jefferies Financial Group began coverage on Kenvue in a report on Tuesday, September 24th. They set a “buy” rating and a $27.00 price target on the stock. Finally, JPMorgan Chase & Co. lifted their price objective on shares of Kenvue from $24.00 to $25.00 and gave the company an “overweight” rating in a research note on Friday, October 11th. One research analyst has rated the stock with a sell rating, eight have assigned a hold rating and three have assigned a buy rating to the company’s stock. According to MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus price target of $22.64.

Kenvue Company Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.